Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-valent human papillomavirus vaccine + elasomeran
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
9-valent human papillomavirus vaccine + elasomeran is a concomitant vaccination regimen consisting of the 9-valent recombinant human papillomavirus (HPV) vaccine (Gardasil 9) and the mRNA-1273 SARS-CoV-2 vaccine (elasomeran). Developed by Merck & Co. and Moderna, this regimen is being evaluated in Phase 3 clinical trials to assess the safety and immunogenicity of administering both vaccines together, particularly in children aged 9 to 11 years. The HPV component provides protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which are associated with cervical cancer and other HPV-related diseases. The mRNA-1273 component is a nucleoside-modified messenger RNA vaccine that encodes the spike protein of the SARS-CoV-2 virus to prevent COVID-19. The study aims to facilitate healthcare delivery by reducing the number of visits required for adolescent immunization.
- Brand names
- Gardasil 9Gardasil9Gardasil-9Spikevax
- Other names
- 9vHPV + mRNA-1273Gardasil 9 + Spikevax
02
Targets
SARS-CoV-2 spikeHPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on 9-valent human papillomavirus vaccine + elasomeran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-valent human papillomavirus vaccine + elasomeran.